Immunotherapeutic targets in non‐small cell lung cancer. Issue 2 (25th August 2022)

• Record Type: Journal Article
• Authors: Sadeghirad, Habib; Bahrami, Tayyeb; Layeghi, Sepideh M.; Yousefi, Hassan; Rezaei, Meysam; Hosseini‐Fard, Seyed R.; Radfar, Payar; Warkiani, Majid E.; O'Byrne, Ken; Kulasinghe, Arutha
• Is Part Of: Immunology. Volume 168:Issue 2(2023)
• Page Start: 256
• Page End: 272
• Publication Date: 2022-08-25
• Subjects: immunotherapy -- non‐small cell lung cancer -- NSCLC -- TME -- tumour microenvironment; Immunology -- Periodicals
• DOI: 10.1111/imm.13562
• Languages: English
• ISSNs: 0019-2805

Abstract

Abstract: Non‐small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5‐year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in‐depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy. Abstract : Adapted from Dong, Q, et al. Front Immunol. 2021;12:956. Created with BioRender.com